Annals of Geriatric Education and Medical Sciences


Full Text PDF Share on Facebook Share on Twitter

Author Details: Anandh K, P. Venkata Krishnan

Volume : 2

Issue : 1

Online ISSN : 2348-7240

Print ISSN : 2348-7348

Article First Page : 13

Article End Page : 16


The role of HMG CoA Reductase inhibitors (Statins) in type 2 Diabetes Mellitus (DM) patients with hypercholesterolemia is undisputable. The ATP III guidelines suggests that diabetes should be considered as a CHD risk equivalent and it advocates that all patients with established CHD or diabetes should achieve a target goal of LDL - C < 100 mg/dl. Statins are considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. There is compelling evidence for the use of statin therapy for CHD risk reduction in such patients with diabetes based on large randomized control trials. The glycaemic status of patients on statin therapy is not a concern until recently. Evidence accrues that statin therapy impairs the glycaemic status. Although the causality is not well proven yet, it demands a focus because whether this is a class effect of all statins or limited to specific statins requires further clarifications. In this light, it becomes important to do a systematic review of the studies using statins and the effect on glycaemic status.